Who is sponsoring NCT00306514?

NCT00306514 is sponsored by Cytos Biotechnology AG.

What drugs are being tested in NCT00306514?

Interventions: CYT004-MelQbG10.

What is the status of NCT00306514?

NCT00306514 is currently COMPLETED.

Last reviewed 2007-09-19 · How we verify

A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma

NCT00306514 Phase 1/Phase 2 COMPLETED

The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.

Details

Lead sponsor	Cytos Biotechnology AG
Phase	Phase 1/Phase 2
Status	COMPLETED

Conditions

Melanoma

Interventions

CYT004-MelQbG10

Countries

Germany